EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Performance of FRAX in Men With Prostate Cancer: A Registry-Based Cohort Study

Carrie Ye iD, Suzanne N Morin iD, Lisa M Lix iD, Eugene V McCloskey iD, Helena Johansson, Nicholas C Harvey iD, John A Kanis, William D Leslie iD

Journal of Bone and Mineral Research · 2020

DOI: 10.1002/jbmr.4793 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Journal of Bone and Mineral Research, 2020. Verfasst von Carrie Ye und 7 weiteren Autor:innen. Beteiligte Einrichtung: University of Alberta, Edmonton, Canada. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Osteoporotic Fractures, Hip Fractures. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The Fracture Risk Assessment Tool (FRAX®) was created to predict major osteoporotic fractures (MOF) and hip fractures in the general population. Whether FRAX accurately predicts fractures in men with prostate cancer is unknown. Our objective was to assess the performance of FRAX for predicting incident fractures in men with prostate cancer. Men from the Manitoba Bone Mineral Density (BMD) Registry (1996–2018) with prostate cancer diagnoses in the 3 years prior to dual-energy X-ray absorptiometry (DXA) were identified. FRAX scores with and without BMD were calculated. From population-based healthcare data we identified incident MOF, hip fracture, any osteoporotic fracture and death from the date of BMD testing to March 31, 2018. Cox regression was performed to estimate hazard ratios (HRs) with 95% confidence intervals (95% CIs) per standard deviation increase in FRAX score. Observed 10-year probability (estimated with competing risk of mortality) was compared with 10-year FRAX-predicted fracture probability to assess calibration. The study population included 684 men with prostate cancer (mean age 74.6 years) and 8608 men without prostate cancer (mean age 65.5 years). FRAX stratified risk for MOF (HR 1.91, 95% CI 1.48–2.45 with BMD; HR 1.96, 95% CI 1.43–2.69 without BMD) and hip fracture (HR 3.37, 95% CI 1.90–6.01 with BMD; HR 4.58, 95% CI 2.17–9.67 without BMD) in men with prostate cancer. There was no effect modification observed with prostate cancer status or current androgen deprivation therapy. Observed 10-year fracture probability in men with prostate cancer showed good agreement with FRAX with and without BMD included in the calculation (observed/predicted calibration ratios MOF 0.97, hip 1.00 with BMD; MOF 0.92, hip 0.93 with BMD). In conclusion, FRAX reliably predicts incident fractures in men with prostate cancer. © 2023 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsOsteoporotic FracturesHip FracturesMaleHumansAgedCohort StudiesAndrogen AntagonistsRisk AssessmentBone DensityAbsorptiometry, PhotonRegistriesRisk Factors

Stichwörter der Autor:innen

CANCERDXAFRACTURE RISK ASSESSMENTGENERAL POPULATION STUDIESOSTEOPOROSIS

Substanzen

Androgen Antagonists

Autor:innen und Institutionen

  • University of Alberta, Edmonton, Canada.
  • McGill University, Montreal, Canada.
  • University of Manitoba, Winnipeg, Canada.
  • Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Sheffield, UK.
  • MRC Versus Arthritis Centre for Integrated Research in Musculoskeletal Ageing, Department of Oncology & Metabolism, University of Sheffield, Sheffield, UK.
  • Mary McKillop Institute for Health Research, Australian Catholic University, Melbourne, Australia.

ORCID-Profile: Carrie Ye, Suzanne N Morin, Lisa M Lix, Eugene V McCloskey, Nicholas C Harvey, William D Leslie

Förderung

  • Medical Research Council

Zitieren

APA

Ye, C., Morin, S. N., Lix, L. M., McCloskey, E. V., Johansson, H., Harvey, N. C., Kanis, J. A., & Leslie, W. D. (2020). Performance of FRAX in Men With Prostate Cancer: A Registry-Based Cohort Study. Journal of Bone and Mineral Research. https://doi.org/10.1002/jbmr.4793

Vancouver

Ye C, Morin SN, Lix LM, McCloskey EV, Johansson H, Harvey NC, et al. Performance of FRAX in Men With Prostate Cancer: A Registry-Based Cohort Study. Journal of Bone and Mineral Research. 2020. doi:10.1002/jbmr.4793

BibTeX
@article{Ye2020,
  author = {Ye, Carrie and Morin, Suzanne N and Lix, Lisa M and McCloskey, Eugene V and Johansson, Helena and Harvey, Nicholas C and Kanis, John A and Leslie, William D},
  title = {Performance of FRAX in Men With Prostate Cancer: A Registry-Based Cohort Study},
  journal = {Journal of Bone and Mineral Research},
  year = {2020},
  doi = {10.1002/jbmr.4793}
}
Kostenlos starten →